Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Enrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027
Enrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027